Answers are grounded in this paper and cite their sources.
Objective: Parkinson’s disease (PD) and alcohol use disorder (AUD) have different clinical profiles, but they may share certain molecular weaknesses. This computer-based study explores the new idea that Glycophorin-E (GYPE) could be a common target for both conditions, with the natural compound oleuropein (OLE) as a possible modulator. Methods: Using structure-based computational methods, we conducted molecular docking and interaction analysis to examine how OLE binds to a modeled GYPE structure. Results: The analysis showed that OLE has a stable and energetically favorable binding position in a proposed active site of GYPE, with a binding strength of -5.3 kcal/mol. The complex’s stability comes from a mix of specific intermolecular forces, including important hydrophobic interactions with Val35 and Tyr39, along with essential hydrogen bonds with Ser30, Thr36, Tyr39, and Gln43. Importantly, Tyr39 plays a dual role by also forming a stabilizing salt bridge, adding notable ionic interaction energy that helps stabilize the overall complex. These findings present the first computer-based evidence for strong and specific binding of OLE to GYPE. Conclusion: We suggest that this interaction could explain how OLE shows neuroprotective and anti-addictive effects by influencing GYPE-related pathways. However, this study has limitations since it is a computer-based analysis. Also, because Glycophorin E is a protein with low biological expression, further in vivo and in vitro studies are needed to confirm its potential effects in the body.
No takes yet. Share an insight, caveat, or question.
Shadidizaji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: